IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9278981 B1

PDFFull Text
Date of Patent:
Mar. 08, 2016

Filed:

May. 09, 2013

Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1

Applicants:

Pascal Furet, Thann, FR;

Robert Martin Grotzfeld, Ettingen, CH;

Wolfgang Jahnke, Lorrach, DE;

Darryl Brynley Jones, Basel, CH;

Paul William Manley, Arlesheim, CH;

Andreas Marzinzik, Weil, DE;

Xavier Francois Andre Pelle, Kembs, FR;

Bahaa Salem, Basel, CH;

Joseph Schoepfer, Riehen, CH;

Erich Alois Spieser, Allschwil, CH;

Inventors:

Pascal Furet, Thann, FR;

Robert Martin Grotzfeld, Ettingen, CH;

Wolfgang Jahnke, Lorrach, DE;

Darryl Brynley Jones, Basel, CH;

Paul William Manley, Arlesheim, CH;

Andreas Marzinzik, Weil, DE;

Xavier Francois Andre Pelle, Kembs, FR;

Bahaa Salem, Basel, CH;

Joseph Schoepfer, Riehen, CH;

Erich Alois Spieser, Allschwil, CH;

Assignee:

Novartis AG, Basel, CH;

Attorney:

Scott W. Reid

Primary Examiner:

Alexander R Pagano

Int. Cl.
CPC ...
A61K 31/4439 (2006.01); C07D 498/08 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 401/04 (2006.01); C07D 401/10 (2006.01); C07D 403/10 (2006.01); C07D 413/10 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 487/10 (2006.01); C07D 491/10 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/4725 (2006.01); A61K 31/498 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/551 (2006.01); A61K 31/553 (2006.01); A61K 45/06 (2006.01); C07D 491/107 (2006.01);
U.S. Cl.
CPC ...
C07D 498/08 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/4725 (2013.01); A61K 31/498 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/551 (2013.01); A61K 31/553 (2013.01); A61K 45/06 (2013.01); C07D 401/04 (2013.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 403/10 (2013.01); C07D 405/14 (2013.01); C07D 413/10 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01); C07D 491/10 (2013.01); C07D 491/107 (2013.01);
Abstract

The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

Find Patent Forward Citations

Loading…